vs
Side-by-side financial comparison of Aeluma, Inc. (ALMU) and Context Therapeutics Inc. (CNTX). Click either name above to swap in a different company.
Aeluma, Inc. is the larger business by last-quarter revenue ($1.3M vs $1.2M, roughly 1.0× Context Therapeutics Inc.). Aeluma, Inc. runs the higher net margin — -145.7% vs -1403.9%, a 1258.2% gap on every dollar of revenue. On growth, Context Therapeutics Inc. posted the faster year-over-year revenue change (328.2% vs -21.1%). Aeluma, Inc. produced more free cash flow last quarter ($-282.0K vs $-1.9M).
Aeluma, Inc. is a U.S.-headquartered technology firm focused on the design, development, and production of high-performance optoelectronic components and semiconductor products. Its core offerings include photonic sensors and laser diodes, serving the LiDAR, 5G/6G communication, industrial sensing, and automotive markets across North America and the Asia-Pacific region.
Context Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative targeted therapies for hormone-driven cancers. Its core pipeline includes candidates for breast, ovarian and other gynecologic malignancies, primarily serving oncology patient populations across North America and Europe.
ALMU vs CNTX — Head-to-Head
Income Statement — Q2 FY2026 vs Q3 FY2024
| Metric | | |
|---|---|---|
| Revenue | $1.3M | $1.2M |
| Net Profit | $-1.9M | $-17.5M |
| Gross Margin | 27.8% | — |
| Operating Margin | -163.6% | -1503.7% |
| Net Margin | -145.7% | -1403.9% |
| Revenue YoY | -21.1% | 328.2% |
| Net Profit YoY | 36.0% | -197.2% |
| EPS (diluted) | $-0.11 | $-0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.3M | — | ||
| Q3 25 | $1.4M | — | ||
| Q3 24 | — | $1.2M | ||
| Q2 24 | — | $840.1K | ||
| Q4 23 | — | $224.7K | ||
| Q3 23 | — | $290.4K | ||
| Q2 23 | — | $293.3K | ||
| Q1 23 | — | $355.5K |
| Q4 25 | $-1.9M | — | ||
| Q3 25 | $-1.5M | — | ||
| Q3 24 | — | $-17.5M | ||
| Q2 24 | — | $-2.3M | ||
| Q4 23 | — | $-6.8M | ||
| Q3 23 | — | $-5.9M | ||
| Q2 23 | — | $-5.0M | ||
| Q1 23 | — | $-6.3M |
| Q4 25 | 27.8% | — | ||
| Q3 25 | 49.4% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — |
| Q4 25 | -163.6% | — | ||
| Q3 25 | -116.1% | — | ||
| Q3 24 | — | -1503.7% | ||
| Q2 24 | — | -367.6% | ||
| Q4 23 | — | -3085.3% | ||
| Q3 23 | — | -2128.0% | ||
| Q2 23 | — | -1804.6% | ||
| Q1 23 | — | -1875.0% |
| Q4 25 | -145.7% | — | ||
| Q3 25 | -107.8% | — | ||
| Q3 24 | — | -1403.9% | ||
| Q2 24 | — | -268.3% | ||
| Q4 23 | — | -3012.6% | ||
| Q3 23 | — | -2022.7% | ||
| Q2 23 | — | -1708.8% | ||
| Q1 23 | — | -1774.3% |
| Q4 25 | $-0.11 | — | ||
| Q3 25 | $-0.09 | — | ||
| Q3 24 | — | $-0.22 | ||
| Q2 24 | — | $-0.04 | ||
| Q4 23 | — | $-0.42 | ||
| Q3 23 | — | $-0.37 | ||
| Q2 23 | — | $-0.31 | ||
| Q1 23 | — | $-0.40 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $38.6M | $84.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $40.8M | $83.9M |
| Total Assets | $42.6M | $86.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $38.6M | — | ||
| Q3 25 | $25.9M | — | ||
| Q3 24 | — | $84.8M | ||
| Q2 24 | — | $101.5M | ||
| Q4 23 | — | $14.4M | ||
| Q3 23 | — | $21.7M | ||
| Q2 23 | — | $25.1M | ||
| Q1 23 | — | $29.8M |
| Q4 25 | $40.8M | — | ||
| Q3 25 | $40.9M | — | ||
| Q3 24 | — | $83.9M | ||
| Q2 24 | — | $101.1M | ||
| Q4 23 | — | $11.9M | ||
| Q3 23 | — | $18.4M | ||
| Q2 23 | — | $24.0M | ||
| Q1 23 | — | $28.7M |
| Q4 25 | $42.6M | — | ||
| Q3 25 | $42.7M | — | ||
| Q3 24 | — | $86.3M | ||
| Q2 24 | — | $102.7M | ||
| Q4 23 | — | $16.1M | ||
| Q3 23 | — | $23.0M | ||
| Q2 23 | — | $27.8M | ||
| Q1 23 | — | $32.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-251.0K | $-1.9M |
| Free Cash FlowOCF − Capex | $-282.0K | $-1.9M |
| FCF MarginFCF / Revenue | -22.2% | -156.0% |
| Capex IntensityCapex / Revenue | 2.4% | 0.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-251.0K | — | ||
| Q3 25 | $-815.0K | — | ||
| Q3 24 | — | $-1.9M | ||
| Q2 24 | — | $-3.4M | ||
| Q4 23 | — | $-7.2M | ||
| Q3 23 | — | $-3.5M | ||
| Q2 23 | — | $-4.6M | ||
| Q1 23 | — | $-5.7M |
| Q4 25 | $-282.0K | — | ||
| Q3 25 | $-1.0M | — | ||
| Q3 24 | — | $-1.9M | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — |
| Q4 25 | -22.2% | — | ||
| Q3 25 | -74.0% | — | ||
| Q3 24 | — | -156.0% | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — |
| Q4 25 | 2.4% | — | ||
| Q3 25 | 15.2% | — | ||
| Q3 24 | — | 0.6% | ||
| Q2 24 | — | 0.0% | ||
| Q4 23 | — | 0.0% | ||
| Q3 23 | — | 0.0% | ||
| Q2 23 | — | 0.0% | ||
| Q1 23 | — | 0.0% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
